High Triglycerides: What the Number Means and What Happens Next

Medically reviewed by Nachiket J. Patel, MD, FACC, FSCAI. Last medically reviewed: August 2026.

Triglycerides appear on the same laboratory report as LDL and HDL cholesterol, but they are not simply another name for cholesterol.

They are a form of fat used to carry and store energy. Their level can change substantially with recent food, alcohol, blood-sugar control, weight, illness, medications, and inherited biology. A high result therefore deserves interpretation, not just a red flag in the patient portal.

Two questions guide the response: Does the pattern increase long-term risk from plaque-forming particles, and is the level high enough to create concern for acute pancreatitis?

One result is a starting point

The 2026 ACC/AHA dyslipidemia guideline defines persistent hypertriglyceridemia as a fasting triglyceride level of at least 150 mg/dL after secondary causes have been evaluated, lifestyle treatment has had time to work, and statin therapy is stable when otherwise indicated.

That definition matters. A single nonfasting level after a large meal or alcohol exposure may need confirmation. A fasting repeat is particularly useful when triglycerides are markedly elevated, pancreatitis prevention is at issue, or a genetic disorder is possible.

Do not postpone a clinician call when the value is very high. Confirmation and action can proceed together.

The level changes the clinical priority

The broad categories used in current adult guidance are practical:

• 150 to 499 mg/dL: The main issue is usually overall cardiovascular and metabolic risk. Triglyceride-rich remnant particles, LDL, non-HDL cholesterol, apoB, blood pressure, diabetes, kidney health, and tobacco exposure should be considered together.
• 500 to 999 mg/dL: Pancreatitis prevention becomes a more immediate concern. Secondary causes, alcohol, diet, and medication options need prompt review.
• 1,000 mg/dL or higher: Chylomicrons often accumulate, and pancreatitis risk is substantially more important. This level requires a timely, coordinated plan with very specific nutrition and medication guidance.

Previous pancreatitis, pregnancy, diabetes control, family history, and the trajectory across several tests can change urgency.

Common reasons triglycerides rise

High triglycerides often result from more than one factor, including:

• Diabetes or rising blood sugar
• Weight gain, insulin resistance, or metabolic syndrome
• Alcohol use
• Foods and drinks high in added sugar or refined carbohydrate
• Chronic kidney, liver, thyroid, or inflammatory disease
• Pregnancy
• Certain medications, including selected steroids, estrogens, diuretics, beta blockers, immune therapies, and other drugs
• A personal or family history suggesting an inherited lipid disorder

Do not stop a prescription because it appears on a list of possible contributors. The indication and alternatives must be considered first. Sometimes a medication is essential and the triglycerides can be managed another way.

Extremely high levels may reflect an inherited disorder. Rare familial chylomicronemia requires specialist evaluation and a plan very different from ordinary moderate elevation.

Food advice should match the degree of elevation

For moderate elevation, useful changes often include reducing added sugar, refined starches, excess saturated fat, and alcohol; increasing activity; and improving diabetes control. Weight reduction can help when appropriate.

Severe hypertriglyceridemia is different. The 2026 guideline recommends no alcohol for fasting levels of 500 to 999 mg/dL, with individualized limitation of total fat. At 1,000 mg/dL or higher, a very-low-fat diet, elimination of alcohol and added sugars, and close clinical guidance may be needed to reduce pancreatitis risk.

A generic “heart healthy” diet or unsupervised high-fat plan may be unsafe with very high triglycerides. A registered dietitian can translate the result into a realistic plan.

Medication decisions are risk-based

Statins remain central when a patient's overall risk calls for LDL and apoB lowering. A statin may not produce the largest percentage drop in triglycerides, but it can reduce the heart-attack and stroke risk that matters most.

Additional treatment depends on the situation. Prescription fibrates or prescription omega-3 products may be considered for selected patients, especially when pancreatitis prevention is the immediate goal. Icosapent ethyl has cardiovascular-outcome evidence in particular higher-risk groups with persistent elevation despite statin therapy; it is not interchangeable with every fish-oil supplement.

Over-the-counter products vary in dose and content. “Natural” does not mean equivalent to a prescription or free of interaction and side-effect considerations.

What a useful follow-up visit should answer

Bring the full lipid panel and earlier results if available. A useful review asks:

• Was the sample fasting, and does it need to be repeated?
• Is blood sugar, thyroid, kidney, liver, alcohol, or a medication contributing?
• Is the immediate concern cardiovascular risk, pancreatitis, or both?
• Are LDL and non-HDL cholesterol sufficient, or would apoB add clarity?
• What specific nutrition change fits this triglyceride range?
• When should the laboratory test be repeated after a change?

The goal is not merely to move one number into the laboratory range. It is to identify the cause, reduce the relevant risk, and choose a plan the patient can follow safely.

When symptoms need urgent care

A triglyceride result by itself does not diagnose pancreatitis. Seek urgent medical assessment for severe, persistent upper-abdominal pain—especially pain that travels to the back—or repeated vomiting. Call 911 for severe pain with fainting, confusion, major weakness, breathing difficulty, or other signs of a medical emergency.

Do not attempt to manage a very high result by fasting for days, stopping diabetes medication, or starting large doses of a supplement without clinical guidance.

Sources and Further Reading

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. Published March 13, 2026.
2. American Heart Association. 2026 Guideline on the Management of Dyslipidemia. Updated March 13, 2026.
3. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. J Am Coll Cardiol. 2021;78:960–993.
4. American Heart Association. Key Patient Messages: 2026 Guideline on the Management of Dyslipidemia.

Related heart and vascular information

• Hyperlipidemia
• Coronary Artery Disease
• The Link Between Diabetes and Heart Disease
• How Much Exercise Is Good for Your Heart?
• Hypertension

Schedule an appointment

If you would like a focused review of your symptoms, risk, testing, or treatment options, request an appointment with Flow Heart & Vascular in Mesa, Arizona.

This article provides general education and does not replace individualized medical advice, diagnosis, or emergency care. Do not start, stop, or change medication or delay emergency care based only on information on this website.